ev3 Inc. Product Pipeline Analysis

SUMMARY

ev3 Inc. Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a ev3 Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

TABLE OF CONTENTS

1 Table of Contents 3
1.1 List of Tables 8
1.2 List of Figures 9
2 Company Snapshot 10
2.1 Key Information 10
2.2 Company Overview 10
2.3 Financial Performance 10
2.4 Industry Outlook -- Cardiovascular Devices 10
3 Business Description 11
3.1 Business Overview 11
3.2 Neurovascular Segment 11
3.2.1 Overview 11
3.2.2 Financials 11
3.2.3 Market View 11
3.2.4 Key Strategies 11
3.3 Peripheral Vascular Segment 11
3.3.1 Overview 11
3.3.2 Financials 12
3.3.3 Market View 12
3.3.4 Key Strategies 12
3.4 Major Products and Services 12
3.4.1 Overview 12
4 History 14
5 Business Strategy 15
5.1 Mission Statement 15
5.2 Strategy 15
6 Value Chain Analysis 16
6.1 Manufacturing 16
6.1.1 In House Manufacturing 16
6.2 Product Development 17
6.2.1 Regulatory Approvals 17
6.2.2 Clinical Trials 17
6.2.3 Research and Development 17
6.3 Sales and Marketing 17
6.3.1 Partnerships and Alliances 17
6.3.2 Licensing Agreements 17
7 Competitors 19
8 Share Holding Structure 20
9 Key Employees 21
10 Key Employee Biographies 22
11 Company Statement 24
12 Locations And Subsidiaries 27
12.1 Head Office 27
12.2 Other Locations & Subsidiaries 27
13 Recent Developments 29
13.1 Financial Announcements 29
13.1.1 Jul 28, 2008: ev3 Reports 2Q 2008 Results 29
13.1.2 May 02, 2008: ev3 Reports Q1 2008 Results 31
13.1.3 Apr 18, 2008: ev3 To Declare Q1 2008 Results 32
13.1.4 Feb 22, 2008: ev3 Reports Q4 2007 Results 32
13.1.5 Feb 08, 2008: ev3 To Declare Q4 And 2007 Results 34
13.1.6 Jan 07, 2008: ev3 Reports Preliminary Q4 2007 Results and Revised 2008 Guidance 34
13.1.7 Oct 31, 2007: ev3 Reports Q3 2007 Results 36
13.1.8 Jul 22, 2007: ev3 Reports Q2 2007 Results 37
13.1.9 Apr 27, 2007: ev3 Reports Q1 2007 Results 39
13.1.10 Feb 20, 2007: ev3 Reports Year-End 2006 Results 40
13.1.11 Oct 20, 2006: ev3 Reports Q3 2006 Results 41
13.1.12 Jul 28, 2006: ev3 Reports Q2 2006 Results 43
13.2 Corporate Communications 44
13.2.1 Aug 04, 2008: ev3 Appoints New Board Member 44
13.2.2 Jul 21, 2008: ev3 Announces Management Changes 44
13.2.3 Apr 07, 2008: ev3 Announces Management Changes 45
13.2.4 Feb 08, 2008: ev3 Chief Scientist And Board Member Resigns 45
13.2.5 Feb 27, 2007: ev3 Appoints New Director 45
13.3 Product News 46
13.3.1 Dec 18, 2007: ev3 Introduces New Enhanced Offering For The Treatment Of Peripheral Artery Disease 46
13.3.2 Dec 18, 2007: ev3 Introduces New Enhanced Offerings For The Treatment Of Peripheral Artery Disease 46
13.3.3 Jun 04, 2007: ev3 Receives Conditional IDE Approval To Study Use Of Protégé EverFlex Self-Expanding Stent System In The Treatment Of Peripheral Artery Disease 46
13.3.4 Feb 15, 2006: SilverHawk Plaque Excision Shown To Minimize The Amputation Rate In Multi-Center Publication Of Patients With Critical Limb Ischemia 47
13.3.5 Apr 11, 2003: Early Results Show PLAATO Device Safe And Feasible For Stroke Prevention In Patients With Atrial Fibrillation 47
13.4 Product Approvals 47
13.4.1 Jun 04, 2007: ev3 Receives Conditional IDE Approval To Study Use Of Protégé EverFlex Self-Expanding Stent System In The Treatment Of Peripheral Artery Disease 47
13.5 Clinical Trials 48
13.5.1 Feb 15, 2006: SilverHawk Plaque Excision Shown To Minimize The Amputation Rate In Multi-Center Publication Of Patients With Critical Limb Ischemia 48
13.5.2 Apr 11, 2003: Early Results Show PLAATO Device Safe And Feasible For Stroke Prevention In Patients With Atrial Fibrillation 48
14 ev3 Inc. Pipeline Products 49
14.1 ev3 Inc. Product Pipeline Analysis 49
14.1.1 ev3 Inc. Pipeline Products By Equipment Type 49
14.1.2 ev3 Inc. Pipeline Products By Development Stage 51
14.1.3 ev3 Inc. Pipeline Products By Therapy Area 52
14.1.4 ev3 Inc. Pipeline Products By Clinical Trials 52
14.1.5 ev3 Inc. Pipeline Products By News Summary 52
14.2 PLAATO 52
14.2.1 Product Description 53
14.2.2 Product Status 53
14.2.3 Clinical Trials 53
14.2.4 Product Milestone 55
14.3 PROTEGE EverFlex Stent 55
14.3.1 Product Description 55
14.3.2 Product Status 55
14.3.3 Clinical Trials 56
14.3.4 Product Milestone 60
14.4 RockHawk Plaque Excision System 61
14.4.1 Product Description 61
14.4.2 Product Status 61
14.4.3 Clinical Trials 61
14.4.4 Product Patent Details 62
14.5 RockHawk for endovascular use 62
14.5.1 Product Description 62
14.5.2 Product Status 63
14.6 Gen II SilverHawk 63
14.6.1 Product Description 63
14.6.2 Product Status 63
14.6.3 Clinical Trials 63
14.6.4 Product Patent Details 64
14.7 Spider Fx 65
14.7.1 Product Description 65
14.7.2 Product Status 65
14.7.3 Clinical Trials 66
14.8 Silver Hawk Peripheral Calcium Tip Plaque Excision System with Spider X Embolic Protection Device 68
14.8.1 Product Description 68
14.8.2 Product Status 68
14.9 Solitaire Stent 68
14.9.1 Product Description 68
14.9.2 Product Status 69
15 Appendix 70
15.1 Methodology 70
15.1.1 Coverage 70
15.1.2 Secondary Research 71
15.1.3 Primary Research 71
15.1.4 Expert Panel Validation 72
15.2 Contact Us 72
15.3 About Global Markets Direct 72
15.4 Disclaimer 72

1.1 List of Tables
Table 1: ev3 Inc.,Key Facts, 2007 10
Table 2: ev3 Inc., Share Holding Structure 20
Table 3: ev3 Inc., Key Employees, 2007 21
Table 4: ev3 Inc., Other Locations 27
Table 5: ev3 Inc., Subsidiaries 28
Table 6: ev3 Inc. Pipeline Products by Equipment Type 50
Table 7: ev3 Inc. Pipeline Products By Development Stage 51
Table 8: ev3 Inc. Pipeline Products By Therapy Area 52
Table 9: ev3 Inc. Pipeline Products By Clinical Trials 52
Table 10: ev3 Inc. Pipeline Products By News Summaries 52

1.2 List of Figures
Figure 1: ev3 Inc., Value Chain Analysis 16
Figure 2: ev3 Inc. Pipeline Products By Equipment Type 49
Figure 3: ev3 Inc. Pipeline Products By Equipment Type 50
Figure 4: ev3 Inc. Pipeline Products By Development Stage 51
Figure 5: Global Markets Direct Methodology 70